Veru Inc. Reports Progress in Clinical Trials and Financials

Veru Inc ( (VERU) ) has released its Q2 earnings. Here is a breakdown of the information Veru Inc presented to its investors.

Veru Inc. is a late clinical-stage biopharmaceutical company that focuses on developing innovative treatments for cardiometabolic and inflammatory diseases. In its fiscal 2025 second-quarter earnings report, Veru Inc. highlighted significant progress in its clinical development programs, particularly with its enobosarm drug, which is being tested for its efficacy in weight management and muscle preservation.

The company reported positive topline results from its Phase 2b QUALITY study, which demonstrated that enobosarm, in combination with semaglutide, significantly reduced lean mass loss and improved body composition by promoting greater fat loss. The study also showed that enobosarm preserved physical function, as evidenced by improved performance in the Stair Climb Test, which is crucial for older adults. Financially, Veru saw an increase in research and development expenses but managed to reduce its net loss compared to the previous year.

Veru’s strategic focus includes advancing its enobosarm program to a Phase 3 clinical trial, aiming to further explore its potential benefits in older patients with obesity or overweight conditions. Additionally, the company is developing a novel oral formulation of enobosarm for future commercialization. Veru is also exploring the use of its anti-inflammatory agent, sabizabulin, for treating inflammation in atherosclerotic cardiovascular disease, highlighting its commitment to addressing significant unmet medical needs.

Looking ahead, Veru Inc. plans to engage with the FDA for regulatory clarity on its Phase 3 clinical program for enobosarm and continues to develop its pipeline with a focus on cardiometabolic diseases. The company remains optimistic about its future prospects, driven by its innovative drug development strategies and ongoing clinical trials.